Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

2.570 +0.190 (+7.98%)
Streaming Delayed Price Updated: 12:48 PM EST, Dec 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fate Therapeutics

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 175.07% to $17.33 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 277.... 
Via Benzinga
38 Stocks Moving In Friday's Mid-Day Session
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing... 
Via Benzinga
Exposures COVID-19
Why Fate Therapeutics Stock Is Sliding Today
The positive results the company announced after the bell yesterday didn't meet some lofty expectations. 
Via The Motley Fool
Mid-Morning Market Update: Markets Rise; Deere Beats Q3 Expectations
Following the market opening Friday, the Dow traded up 0.42% to 35,041.98 while the NASDAQ rose 0.86% to 14,667.29. The S&P also rose, gaining 0.52% to 4,428.90. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) shares... 
Via Benzinga
11 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 74.65% to $7.51. The market value of their outstanding shares is at $47.5 million. Agile Therapeutics (NASDAQ:AGRX... 
Via Benzinga
Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response
Fate Therapeutics Inc (NASDAQ: FATE) revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma. At the 2021... 
Via Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
Fate Stock Collapses As Investors Question Its Cancer Drug's Durability
Fate Therapeutics unveiled mixed results for its lymphoma treatment late Thursday, and Fate stock crumbled in after-hours action. 
Via Investor's Business Daily
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Fate Therapeutics, inc (FATE) Q2 2021 Earnings Call Transcript
FATE earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Did You See What Cathie Wood Bought on Wednesday?
ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks. 
Via The Motley Fool
Unusual Options Activity Insight: Fate Therapeutics
On Monday, shares of Fate Therapeutics (NASDAQ:FATE) saw unusual options activity. After the option alert, the stock price moved down to $88. Sentiment: BEARISH Option Type:... 
Via Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
Elliott Wave Technical Analysis For Six US Stocks - CDNA, CRWD, FATE, UPS, HDB, SPOT
CareDx, CrowdStrike, Fate Therapeutics, HDFC Bank, Spotify, ​​​​​​​UPS - Daily charts. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2021
Upgrades Deutsche Bank upgraded the previous rating for Marriott Vacations Worldwide Corp (NYSE:VAC) from Hold to Buy. Marriott Vacations earned $0.49 in the first quarter... 
Via Benzinga
Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21
Fate Therapeutics Inc (NASDAQ: FATE) has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed / refractory B-cell... 
Via Benzinga
Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients
Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Bionano Genomics (NASDAQ:BNGO) st... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics... 
Via Benzinga
Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com
Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc (NASDAQ: JD), a key rival to Alibaba Group Holding (NYSE: BABA... 
Via Benzinga
Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings
Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ: 
Via Benzinga
Fate Therapeutics Inc (FATE) Q1 2021 Earnings Call Transcript
FATE earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Preview: Fate Therapeutics's Earnings
On Wednesday, May 05, Fate Therapeutics (NASDAQ:FATE) will release its latest earnings report. Benzinga's outlook for Fate Therapeutics is included in the following report. Net... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know
Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.